Stemcell United Limited, together with its subsidiaries, engages in the sourcing, producing, marketing, and selling of traditional medicines in Australia, Singapore, Greater China, and Malaysia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.014|
|52 Week High||AU$0.012|
|52 Week Low||AU$0.049|
|1 Month Change||0%|
|3 Month Change||-30.00%|
|1 Year Change||-22.22%|
|3 Year Change||-39.13%|
|5 Year Change||7.69%|
|Change since IPO||-99.96%|
Recent News & Updates
|SCU||AU Biotechs||AU Market|
Return vs Industry: SCU underperformed the Australian Biotechs industry which returned 1.7% over the past year.
Return vs Market: SCU underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: SCU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: SCU's weekly volatility has decreased from 18% to 10% over the past year.
About the Company
Stemcell United Limited, together with its subsidiaries, engages in the sourcing, producing, marketing, and selling of traditional medicines in Australia, Singapore, Greater China, and Malaysia. Its products include Caulerpa Lentillifera, a sea grape extract; Dendrobium Officinale Kimura et Migo, an orchid; Resina, a Daemonorops Draco Blume extract; and Cannabis Sativa, an industrial hemp. The company has a collaboration agreement with Temasek Polytechnic of Singapore to conduct joint research on the application of plant stem cell technology to the cultivation and commercial farming of seagrapes in Singapore; collaboration with Yunnan Hongyi Agriculture Development Co Ltd; and collaboration agreement with the University of Science, Malaysia to study the cultivation of sea grapes through the use of land-based and urban farming techniques.
Stemcell United Fundamentals Summary
|SCU fundamental statistics|
Is SCU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SCU income statement (TTM)|
|Cost of Revenue||AU$6.95m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.003|
|Net Profit Margin||-36.88%|
How did SCU perform over the long term?See historical performance and comparison
Is Stemcell United undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SCU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SCU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SCU is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: SCU is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SCU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SCU is good value based on its PB Ratio (2.8x) compared to the AU Biotechs industry average (4.8x).
How is Stemcell United forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Stemcell United has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Stemcell United performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SCU is currently unprofitable.
Growing Profit Margin: SCU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SCU is unprofitable, but has reduced losses over the past 5 years at a rate of 66.3% per year.
Accelerating Growth: Unable to compare SCU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: SCU has a negative Return on Equity (-46.11%), as it is currently unprofitable.
How is Stemcell United's financial position?
Financial Position Analysis
Short Term Liabilities: SCU's short term assets (A$8.3M) exceed its short term liabilities (A$2.9M).
Long Term Liabilities: SCU's short term assets (A$8.3M) exceed its long term liabilities (A$113.0K).
Debt to Equity History and Analysis
Debt Level: SCU's debt to equity ratio (12.8%) is considered satisfactory.
Reducing Debt: SCU's debt to equity ratio has increased from 4% to 12.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SCU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SCU has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 9.8% each year.
What is Stemcell United current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SCU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SCU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SCU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SCU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SCU's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Huanqing Gu, also known as Philip, serves as MD & Chief Executive Officer of Stemcell United Limited. Mr. Gu has been a Director of Stemcell United Limited since September 14, 2015. Mr. Gu has experien...
Experienced Board: SCU's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 62.6%.
Stemcell United Limited's employee growth, exchange listings and data sources
- Name: Stemcell United Limited
- Ticker: SCU
- Exchange: ASX
- Founded: 1984
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$14.606m
- Shares outstanding: 1.04b
- Website: https://www.scu.com.sg
- Stemcell United Limited
- 126 Phillip Street
- Level 5
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 07:05|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.